Context: India has been witnessing a huge surge of COVID-19 cases, with increasing number of new cases and deaths daily. There is yet no effective vaccine, drug or strategy to combat this disease. Various models of COVID-19 trend and management have been put forward by different researchers, yet no prediction has yet turned out to be close to the reality.
Aims: To find an effective public health strategy against COVID control.
Settings And Design: Ahmedabad district in Gujarat.
Methods And Material: Ahmedabad Model for control of COVID-19 based on Ct threshold has been put forth which stresses upon the fact that higher viral load (super-spreaders) could be an important determinant in spreading infections in the community.
Results: The cycle threshold (Ct)-based segregation of laboratory-confirmed positive cases along with contact tracing of all of them of previous 5 days has been found to be effective strategy and needs to be adopted for further management. The Ahmedabad model of COVID-19 control was practiced during 3rd week of June 2020 onwards. Following implementation, cases started declining in Ahmedabad district whereas it showed an increasing trend in rest of Gujarat where it was not implemented.
Conclusions: Cases with low viral load may be quarantined at home with standard precaution whereas cases with higher viral load need to be quarantined in institutions (hospital or separate premises away from family).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842441 | PMC |
| http://dx.doi.org/10.4103/jfmpc.jfmpc_1379_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Point-of-care nucleic acid testing - a step forward in controlling the HIV epidemic: A review.
HIV Med
January 2025
Centre for Immunology and Vaccinology, Imperial College London, London, UK.
Introduction: The HIV/AIDS epidemic, with 85.6 million infections and 40.4 million AIDS-related deaths globally, remains a critical public health challenge.
View Article and Find Full Text PDFAcceptability and Feasibility of Self-Collected Dried Blood Spot Specimens for Viral Load Monitoring among Rural Older People Living with HIV.
AIDS Behav
January 2025
Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 2153 N. Dr. Martin Luther King Jr. Dr., Milwaukee, WI, 53212, USA.
Self-collected dried blood spot (DBS) samples may be useful in monitoring viral load (VL) in research studies or clinically given that they eliminate the need for participants to travel to study sites or laboratories. Despite this, little information exists about monitoring VL using DBS self-collected at home, and no information exists on DBS for this use among older rural people living with HIV (PLH), a population that could benefit from self-collection given difficulty accessing care. We report on the feasibility and acceptability of self-collected DBS samples, DBS VL results, concordance between self-reported and DBS VL, and factors associated with DBS detectable VL in a rural Southern U.
View Article and Find Full Text PDFEmpowerment through knowledge: Qualitative perceptions of 'undetectable equals Untransmittable' among people living with HIV and tuberculosis in South Africa.
Int J Nurs Stud
January 2025
Johns Hopkins University Center for Infectious Disease and Nursing Innovation, Baltimore, MD, USA; Johns Hopkins University School of Nursing, Baltimore, MD, USA.
Introduction: Undetectable equals untransmittable (U=U) is an education campaign promoting science that people living with human immunodeficiency virus (HIV) who maintain an undetectable viral load cannot transmit HIV to others. Researchers theorize that undetectable equals untransmittable messaging will decrease HIV stigma by reducing fears of HIV transmission and providing evidence to dismantle discriminatory policies. However, little is known about how people with HIV in South Africa interpret the results of their viral load tests, undetectable equals untransmittable messaging, or its impact on stigma.
View Article and Find Full Text PDFEfficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Virol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFAGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.
Gastroenterology
February 2025
Section of Gastroenterology and Hepatology, Veterans Affairs Northeast Ohio Health Care System, Cleveland, Ohio; Division of Gastroenterology and Hepatology, Case Western Reserve University, Cleveland, Ohio.
Background & Aims: Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating the risk of HBVr. In select cases, clinical monitoring without antiviral prophylaxis is sufficient for managing the risk of HBVr.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!